{"id":2300,"date":"2022-03-15T09:57:25","date_gmt":"2022-03-15T09:57:25","guid":{"rendered":"http:\/\/120.72.95.94:55147\/?p=2300"},"modified":"2024-05-24T11:56:48","modified_gmt":"2024-05-24T18:56:48","slug":"affderm-en-las-noticias-55a-reunion-anual-de-la-sociedad-americana-de-dermatopatologia","status":"publish","type":"post","link":"https:\/\/affderm.com\/es\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/","title":{"rendered":"AffDerm en las noticias: 55.\u00aa Reuni\u00f3n Anual de la Sociedad Americana de Dermatopatolog\u00eda"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"2300\" class=\"elementor elementor-2300\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9cb5c19 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9cb5c19\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fa50cfa\" data-id=\"fa50cfa\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7c74308 elementor-widget elementor-widget-text-editor\" data-id=\"7c74308\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"epi-fontLg bwalignc\"><strong>Enhorabuena al Dr.\u00a0<span id=\"0.7829400770644677\" class=\"currentHitHighlight\">Estrada<\/span>\u00a0por su reportaje en Business Wire sobre su labor cient\u00edfica en las pruebas del melanoma. M\u00e1s informaci\u00f3n sobre el reciente estudio sobre el futuro de los riesgos de c\u00e1ncer de piel en los pacientes.<\/strong><br \/><span id=\"more-3713\"><\/span><\/p><div class=\"bw-release-body\"><div class=\"bw-release-story\"><p>FRIENDSWOOD, Texas-(<a href=\"https:\/\/www.businesswire.com\/\" rel=\"nofollow\">BUSINESS WIRE<\/a>)-Castle Biosciences, Inc. la empresa de diagn\u00f3stico del c\u00e1ncer de piel que ofrece diagn\u00f3sticos moleculares para mejorar las decisiones sobre el tratamiento del c\u00e1ncer, ha anunciado hoy los resultados de un estudio que demuestran que la prueba DecisionDx-Melanoma predice con exactitud el riesgo de los pacientes con melanoma cut\u00e1neo cuando se utiliza la biopsia o la escisi\u00f3n local amplia (WLE) como fuente de tejido. Los aspectos m\u00e1s destacados del estudio se presentaron durante una ponencia oral en la American Society of Dermatopathology 55<sup>th<\/sup>Reuni\u00f3n anual celebrada del 8 al 11 de noviembre de 2018 en Chicago.<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c1a227c elementor-widget elementor-widget-text-editor\" data-id=\"c1a227c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p id=\"pull-quote\">\"El uso de biopsia o tejido de escisi\u00f3n local amplia no afecta a la capacidad de la prueba DecisionDx-Melanoma para predecir con precisi\u00f3n el riesgo e informar las decisiones de gesti\u00f3n del paciente\".<\/p><p><a id=\"tweet-pull-quote\" href=\"https:\/\/www.businesswire.com\/news\/home\/20181113005335\/en\/Study-Demonstrating-Accuracy-DecisionDx-Melanoma-Prognostic-Test-Melanoma#\">Twittear<\/a><\/p><p>\"Este estudio demuestra que la prueba DecisionDx-Melanoma proporciona una predicci\u00f3n precisa e independiente del riesgo independientemente de la fuente del tejido\", dijo Sarah Estrada, M.D., FACP, Affiliated Dermatology, Scottsdale AZ, investigadora del estudio. \"El uso de biopsia o tejido de escisi\u00f3n local amplia no afecta a la capacidad de la prueba DecisionDx-Melanoma para predecir con precisi\u00f3n el riesgo e informar las decisiones de gesti\u00f3n del paciente\".<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-60aab0b elementor-widget elementor-widget-text-editor\" data-id=\"60aab0b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"bw-release-body\"><div class=\"bw-release-story\"><p><b>Antecedentes del estudio<\/b><\/p><ul><li class=\"bwlistitemmargb\">Se ha demostrado que la prueba DecisionDx-Melanoma proporciona una predicci\u00f3n precisa e independiente del riesgo de los pacientes con melanoma cut\u00e1neo.<\/li><li class=\"bwlistitemmargb\">La prueba ha demostrado una s\u00f3lida fiabilidad anal\u00edtica con una concordancia interensayo de 99% y una concordancia intraensayo de 100%. El \u00e9xito t\u00e9cnico super\u00f3 los 98% en muestras con suficiente contenido tumoral.<\/li><li class=\"bwlistitemmargb\">Este estudio evalu\u00f3 si los resultados de las pruebas o los resultados de los pacientes estaban asociados con la fuente tisular (biopsia o WLE) en una cohorte de archivo de 537 pacientes con melanoma cut\u00e1neo en estadio I-III de los que se conoc\u00eda la fuente tisular.<\/li><\/ul><p><b>Principales resultados del estudio<\/b><\/p><ul><li class=\"bwlistitemmargb\">Entre los que se sometieron a pruebas de tejido de biopsia, un mayor porcentaje presentaba enfermedad en estadio I (68%) en comparaci\u00f3n con los que se sometieron a pruebas de tejido de LEOC (19% estadio I; p&lt;0,001).<\/li><li class=\"bwlistitemmargb\">Los pacientes en los que se analiz\u00f3 tejido WLE ten\u00edan una probabilidad significativamente mayor de presentar melanoma en estadio III (50%) en comparaci\u00f3n con los que se analiz\u00f3 tejido de biopsia (17% estadio III; p&lt;0,001).<\/li><li class=\"bwlistitemmargb\">Los pacientes que se sometieron a pruebas de tejido WLE tambi\u00e9n ten\u00edan m\u00e1s probabilidades de presentar caracter\u00edsticas patol\u00f3gicas de mayor riesgo, como ulceraci\u00f3n y aumento del grosor de Breslow.<\/li><li class=\"bwlistitemmargb\">Para ambas fuentes de tejido, los pacientes que obtuvieron el resultado de menor riesgo en la prueba DecisionDx-Melanoma (Clase 1A) tuvieron una supervivencia libre de met\u00e1stasis a distancia y unas tasas de supervivencia espec\u00edficas del melanoma significativamente mejores que los que obtuvieron el resultado de mayor riesgo (Clase 2B).<\/li><li class=\"bwlistitemmargb\">Tras ajustar por caracter\u00edsticas patol\u00f3gicas entre los pacientes de los dos grupos de fuentes de tejido, el uso de tejido WLE no se asoci\u00f3 significativamente con el resultado de la clase de prueba DecisionDx-Melanoma.<\/li><li class=\"bwlistitemmargb\">En el an\u00e1lisis multivariante, DecisionDx-Melanoma Clase 2B (riesgo m\u00e1s alto) fue un predictor independiente significativo de recurrencia, met\u00e1stasis a distancia y supervivencia espec\u00edfica del melanoma, mientras que la fuente tisular WLE no result\u00f3 ser predictiva de los resultados.<\/li><li class=\"bwlistitemmargb\">Estos resultados demuestran que la prueba DecisionDx-Melanoma proporciona una predicci\u00f3n precisa e independiente del riesgo, independientemente del origen del tejido.<\/li><\/ul><p><b>Acerca de DecisionDx-Melanoma<\/b><\/p><p>La prueba DecisionDx-Melanoma utiliza la biolog\u00eda tumoral para predecir el riesgo individual de recurrencia del melanoma y la positividad del ganglio linf\u00e1tico centinela independientemente de los factores tradicionales. Utilizando tejido del melanoma primario, la prueba mide la expresi\u00f3n de 31 genes. La prueba ha sido validada en tres estudios multic\u00e9ntricos que han incluido a 690 pacientes y han demostrado resultados consistentes. El rendimiento tambi\u00e9n se ha confirmado en cuatro estudios prospectivos que han incluido a 702 pacientes. El alto rendimiento y la precisi\u00f3n constantes demostrados en estos estudios, que en conjunto han incluido a m\u00e1s de 1.300 pacientes, proporcionan confianza en los planes de tratamiento de la enfermedad que incorporan los resultados de la prueba DecisionDx-Melanoma.<\/p><p>La predicci\u00f3n de la probabilidad de positividad del ganglio linf\u00e1tico centinela tambi\u00e9n se ha validado en dos estudios prospectivos multic\u00e9ntricos que incluyeron a m\u00e1s de 1.400 pacientes. En estudios multic\u00e9ntricos y unic\u00e9ntricos se ha demostrado el impacto en los planes de tratamiento de una de cada dos pacientes sometidas a la prueba. Puede encontrar m\u00e1s informaci\u00f3n sobre la prueba y la enfermedad en\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SkinMelanoma.com&amp;esheet=51898846&amp;newsitemid=20181113005335&amp;lan=en-US&amp;anchor=www.SkinMelanoma.com&amp;index=1&amp;md5=6c5e8582b1540280ff0113afb30bc2b6\" target=\"_blank\" rel=\"nofollow noopener\">www.SkinMelanoma.com<\/a>.<\/p><p><b>Acerca de Castle Biosciences<\/b><\/p><p>Castle Biosciences es una empresa de diagn\u00f3stico molecular dedicada a ayudar a los pacientes y a sus m\u00e9dicos a tomar las mejores decisiones posibles sobre su tratamiento y cuidados de seguimiento bas\u00e1ndose en la firma molecular individual de su tumor. La empresa ofrece actualmente pruebas para pacientes con melanoma cut\u00e1neo (DecisionDx<sup>\u00ae<\/sup>-Melanoma, DecisionDx<sup>\u00ae<\/sup>-CM<i>Seq<\/i>;\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SkinMelanoma.com&amp;esheet=51898846&amp;newsitemid=20181113005335&amp;lan=en-US&amp;anchor=www.SkinMelanoma.com&amp;index=2&amp;md5=9623da911dd1b9f66937c56b2f038035\" target=\"_blank\" rel=\"nofollow noopener\">www.SkinMelanoma.com<\/a>) y melanoma uveal (DecisionDx<sup>\u00ae<\/sup>-UM, DecisionDx<sup>\u00ae<\/sup>-PRAME y DecisionDx<sup>\u00ae<\/sup>-UM<i>Seq<\/i>;\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.MyUvealMelanoma.com&amp;esheet=51898846&amp;newsitemid=20181113005335&amp;lan=en-US&amp;anchor=www.MyUvealMelanoma.com&amp;index=3&amp;md5=8f2883e6c912823dddfb0def64ca4bd1\" target=\"_blank\" rel=\"nofollow noopener\">www.MyUvealMelanoma.com<\/a>), con programas de desarrollo en otros tipos de c\u00e1ncer desatendidos, el m\u00e1s avanzado de los cuales se centra en pacientes con carcinoma escamoso cut\u00e1neo. Castle Biosciences tiene su sede en Friendswood, Texas (Houston), y un laboratorio en Phoenix, Arizona. M\u00e1s informaci\u00f3n en\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CastleBiosciences.com&amp;esheet=51898846&amp;newsitemid=20181113005335&amp;lan=en-US&amp;anchor=www.CastleBiosciences.com&amp;index=4&amp;md5=d81ac65b813fc33368d0218a695bb7e4\" target=\"_blank\" rel=\"nofollow noopener\">www.CastleBiosciences.com<\/a>.<\/p><p>DecisionDx-Melanoma, DecisionDx-CM<i>Seq<\/i>DecisionDx-UM, DecisionDx-PRAME y DecisionDx-UM<i>Seq<\/i>\u00a0son marcas comerciales de Castle Biosciences, Inc. Cualquier otra marca comercial pertenece a sus respectivos propietarios.<\/p><\/div><div class=\"bw-release-contact\"><h2>Contactos<\/h2><p>Castle Biosciences, Inc.<br \/>Derek Maetzold, 866-788-9007<br \/>Presidente y Consejero Delegado<br \/><a href=\"mailto:IR@castlebiosciences.com\" target=\"_blank\" rel=\"noopener\">IR@castlebiosciences.com<\/a><\/p><\/div><\/div><div><h5><em>Publicado originalmente por<span class=\"entry-author\">\u00a0<a title=\"Publicado por Fabulous Arizona\" href=\"https:\/\/www.businesswire.com\/news\/home\/20181113005335\/en\/Study-Demonstrating-Accuracy-DecisionDx-Melanoma-Prognostic-Test-Melanoma\" target=\"_blank\" rel=\"author noopener\">Business Wire.<\/a><\/span>\u00a0\"<b>El estudio DecisionDx-Melanoma Prognostic Test Demonstrating Accuracy across Melanoma Tissue Sources se presenta en la American Society of Dermatopathology 55<\/b><sup><b>th<\/b><\/sup><b>\u00a0Reuni\u00f3n anual.<\/b>\" 13 de noviembre de 2018 07:00 AM.<\/em><\/h5><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Congratulations to Dr.\u00a0Estrada\u00a0for her feature in Business Wire on\u00a0her scientific\u00a0work in\u00a0melanoma testing. Read more about the recent\u00a0study\u00a0on the future of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2301,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-affiliated-dermatology-updates"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting - Affiliated Dermatology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/affderm.com\/es\/affderm-en-las-noticias-55a-reunion-anual-de-la-sociedad-americana-de-dermatopatologia\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting - Affiliated Dermatology\" \/>\n<meta property=\"og:description\" content=\"Congratulations to Dr.\u00a0Estrada\u00a0for her feature in Business Wire on\u00a0her scientific\u00a0work in\u00a0melanoma testing. Read more about the recent\u00a0study\u00a0on the future of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/affderm.com\/es\/affderm-en-las-noticias-55a-reunion-anual-de-la-sociedad-americana-de-dermatopatologia\/\" \/>\n<meta property=\"og:site_name\" content=\"Affiliated Dermatology\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-15T09:57:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-24T18:56:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92-1200x675.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminaff\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminaff\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/\"},\"author\":{\"name\":\"adminaff\",\"@id\":\"https:\\\/\\\/affderm.com\\\/#\\\/schema\\\/person\\\/2c23376fe825a37257230a8c9f481131\"},\"headline\":\"AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting\",\"datePublished\":\"2022-03-15T09:57:25+00:00\",\"dateModified\":\"2024-05-24T18:56:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/\"},\"wordCount\":796,\"image\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/affderm.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/affderm-92.png\",\"articleSection\":[\"Affiliated Dermatology Updates\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/\",\"name\":\"AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting - Affiliated Dermatology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/affderm.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/affderm-92.png\",\"datePublished\":\"2022-03-15T09:57:25+00:00\",\"dateModified\":\"2024-05-24T18:56:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/#\\\/schema\\\/person\\\/2c23376fe825a37257230a8c9f481131\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/affderm.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/affderm-92.png\",\"contentUrl\":\"https:\\\/\\\/affderm.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/affderm-92.png\",\"width\":2140,\"height\":1203},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/affderm.com\\\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/affderm.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AffDerm in the News: American Society of Dermatopa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/affderm.com\\\/#website\",\"url\":\"https:\\\/\\\/affderm.com\\\/\",\"name\":\"Affiliated Dermatology\",\"description\":\"Experts in Skin Disease Treatment &amp; Prevention\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/affderm.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/affderm.com\\\/#\\\/schema\\\/person\\\/2c23376fe825a37257230a8c9f481131\",\"name\":\"adminaff\",\"sameAs\":[\"https:\\\/\\\/affderm.com\\\/affderm.com\"],\"url\":\"https:\\\/\\\/affderm.com\\\/es\\\/author\\\/adminaff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AffDerm en las noticias: 55\u00aa Reuni\u00f3n Anual de la Sociedad Americana de Dermatopatolog\u00eda - Affiliated Dermatology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/affderm.com\/es\/affderm-en-las-noticias-55a-reunion-anual-de-la-sociedad-americana-de-dermatopatologia\/","og_locale":"es_MX","og_type":"article","og_title":"AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting - Affiliated Dermatology","og_description":"Congratulations to Dr.\u00a0Estrada\u00a0for her feature in Business Wire on\u00a0her scientific\u00a0work in\u00a0melanoma testing. Read more about the recent\u00a0study\u00a0on the future of [&hellip;]","og_url":"https:\/\/affderm.com\/es\/affderm-en-las-noticias-55a-reunion-anual-de-la-sociedad-americana-de-dermatopatologia\/","og_site_name":"Affiliated Dermatology","article_published_time":"2022-03-15T09:57:25+00:00","article_modified_time":"2024-05-24T18:56:48+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92-1200x675.png","type":"image\/png"}],"author":"adminaff","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminaff","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/"},"author":{"name":"adminaff","@id":"https:\/\/affderm.com\/#\/schema\/person\/2c23376fe825a37257230a8c9f481131"},"headline":"AffDerm in the News: American Society of Dermatopathology 55th Annual Meeting","datePublished":"2022-03-15T09:57:25+00:00","dateModified":"2024-05-24T18:56:48+00:00","mainEntityOfPage":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/"},"wordCount":796,"image":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92.png","articleSection":["Affiliated Dermatology Updates"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/","url":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/","name":"AffDerm en las noticias: 55\u00aa Reuni\u00f3n Anual de la Sociedad Americana de Dermatopatolog\u00eda - Affiliated Dermatology","isPartOf":{"@id":"https:\/\/affderm.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92.png","datePublished":"2022-03-15T09:57:25+00:00","dateModified":"2024-05-24T18:56:48+00:00","author":{"@id":"https:\/\/affderm.com\/#\/schema\/person\/2c23376fe825a37257230a8c9f481131"},"breadcrumb":{"@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#primaryimage","url":"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92.png","contentUrl":"https:\/\/affderm.com\/wp-content\/uploads\/2022\/03\/affderm-92.png","width":2140,"height":1203},{"@type":"BreadcrumbList","@id":"https:\/\/affderm.com\/affderm-in-the-news-american-society-of-dermatopathology-55th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/affderm.com\/"},{"@type":"ListItem","position":2,"name":"AffDerm in the News: American Society of Dermatopa"}]},{"@type":"WebSite","@id":"https:\/\/affderm.com\/#website","url":"https:\/\/affderm.com\/","name":"Dermatolog\u00eda afiliada","description":"Expertos en tratamiento y prevenci\u00f3n de enfermedades cut\u00e1neas","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/affderm.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/affderm.com\/#\/schema\/person\/2c23376fe825a37257230a8c9f481131","name":"adminaff","sameAs":["https:\/\/affderm.com\/affderm.com"],"url":"https:\/\/affderm.com\/es\/author\/adminaff\/"}]}},"_links":{"self":[{"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/posts\/2300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/comments?post=2300"}],"version-history":[{"count":0,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/posts\/2300\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/media\/2301"}],"wp:attachment":[{"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/media?parent=2300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/categories?post=2300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/affderm.com\/es\/wp-json\/wp\/v2\/tags?post=2300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}